> top > docs > PubMed:28321439 > annotations

PubMed:28321439 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T5 18-37 D010300 denotes Parkinson's Disease
T6 18-37 D010300 denotes Parkinson's Disease
T9 49-57 SO:0000109 denotes Mutation
T10 58-63 PR:Q5S006 denotes LRRK2
T11 58-63 PR:000003033 denotes LRRK2
T12 58-63 PR:Q5S007 denotes LRRK2
T13 74-79 10090 denotes Mouse
T14 74-79 D051379 denotes Mouse
T15 80-89 UBERON:0001890 denotes Forebrain
T17 124-133 P37379 denotes Synuclein
T16 124-133 D051843 denotes Synuclein
T19 162-169 6308 denotes leucine
T20 162-169 SO:0001437 denotes leucine
T18 162-169 CHEBI:15603 denotes leucine
T21 162-169 D007930 denotes leucine
T22 162-169 CHEBI:25017 denotes leucine
T23 162-169 D007930 denotes leucine
T24 175-181 SO:0001068 denotes repeat
T25 192-197 PR:Q5S006 denotes LRRK2
T26 192-197 PR:000003033 denotes LRRK2
T27 192-197 PR:Q5S007 denotes LRRK2
T28 199-203 SO:0000704 denotes gene
T29 252-262 D000067562 denotes late-onset
T30 252-262 D000067562 denotes late-onset
T31 264-282 C566739 denotes autosomal-dominant
T36 292-311 D010300 denotes Parkinson's disease
T37 292-311 D010300 denotes Parkinson's disease
T40 321-326 PR:Q5S006 denotes LRRK2
T41 321-326 PR:000003033 denotes LRRK2
T42 321-326 PR:Q5S007 denotes LRRK2
T43 418-428 SO:0000781 denotes transgenic
T44 418-433 10090 denotes transgenic mice
T45 418-433 D008822 denotes transgenic mice
T46 429-433 PR:000005054 denotes mice
T48 429-433 O89094 denotes mice
T50 445-454 SO:0000817 denotes wild-type
T51 465-470 PR:Q5S006 denotes LRRK2
T52 465-470 PR:000003033 denotes LRRK2
T53 465-470 PR:Q5S007 denotes LRRK2
T54 515-520 PR:Q5S006 denotes LRRK2
T55 515-520 PR:000003033 denotes LRRK2
T56 515-520 PR:Q5S007 denotes LRRK2
T57 631-637 SO:0000417 denotes domain
T58 666-670 32644 denotes none
T59 678-682 PR:000005054 denotes mice
T61 678-682 O89094 denotes mice
T60 678-682 D051379 denotes mice
T62 678-682 10095 denotes mice
T63 719-724 D006801 denotes human
T64 725-732 D004194 denotes disease
T65 725-732 D004194 denotes disease
T66 798-803 PR:Q5S006 denotes LRRK2
T67 798-803 PR:000003033 denotes LRRK2
T68 798-803 PR:Q5S007 denotes LRRK2
T69 812-817 PR:Q5S006 denotes LRRK2
T70 812-817 PR:000003033 denotes LRRK2
T71 812-817 PR:Q5S007 denotes LRRK2
T72 866-871 PR:Q5S006 denotes LRRK2
T73 866-871 PR:000003033 denotes LRRK2
T74 866-871 PR:Q5S007 denotes LRRK2
T75 887-892 PR:Q5S006 denotes LRRK2
T76 887-892 PR:000003033 denotes LRRK2
T77 887-892 PR:Q5S007 denotes LRRK2
T78 915-920 PR:Q5S006 denotes LRRK2
T79 915-920 PR:000003033 denotes LRRK2
T80 915-920 PR:Q5S007 denotes LRRK2
T81 927-932 PR:Q5S006 denotes LRRK2
T82 927-932 PR:000003033 denotes LRRK2
T83 927-932 PR:Q5S007 denotes LRRK2
T84 978-981 PR:M9NEY8 denotes tet
T85 978-981 O59196 denotes tet
T88 1018-1030 10395 denotes tetracycline
T86 1018-1030 D013752 denotes tetracycline
T87 1018-1030 CHEBI:27902 denotes tetracycline
T89 1018-1030 D013752 denotes tetracycline
T90 1018-1030 CHEBI:77932 denotes tetracycline
T91 1031-1045 D015534 denotes transactivator
T96 1046-1053 SO:0000104 denotes protein
T95 1046-1053 PR:000000001 denotes protein
T93 1046-1053 CHEBI:36080 denotes protein
T94 1046-1053 CHEBI:11122 denotes protein
T92 1046-1053 GO:0003675 denotes protein
T100 1067-1073 PR:Q00168 denotes CAMKII
T101 1067-1073 PR:000003197 denotes CAMKII
T98 1067-1073 D054732 denotes CAMKII
T97 1067-1073 GO:0005954 denotes CAMKII
T99 1067-1073 GO:0004683 denotes CAMKII
T102 1075-1083 SO:0000167 denotes promoter
T106 1085-1091 PR:Q00168 denotes CAMKII
T107 1085-1091 PR:000003197 denotes CAMKII
T104 1085-1091 D054732 denotes CAMKII
T103 1085-1091 GO:0005954 denotes CAMKII
T105 1085-1091 GO:0004683 denotes CAMKII
T108 1125-1130 PR:Q5S006 denotes LRRK2
T109 1125-1130 PR:000003033 denotes LRRK2
T110 1125-1130 PR:Q5S007 denotes LRRK2
T111 1142-1147 PR:Q5S006 denotes LRRK2
T112 1142-1147 PR:000003033 denotes LRRK2
T113 1142-1147 PR:Q5S007 denotes LRRK2
T114 1161-1166 10090 denotes mouse
T115 1161-1166 D051379 denotes mouse
T116 1167-1176 UBERON:0001890 denotes forebrain
T117 1196-1201 PR:Q5S006 denotes LRRK2
T118 1196-1201 PR:000003033 denotes LRRK2
T119 1196-1201 PR:Q5S007 denotes LRRK2
T120 1208-1213 10090 denotes mouse
T121 1208-1213 D051379 denotes mouse
T122 1214-1223 UBERON:0001890 denotes forebrain
T124 1258-1267 P37379 denotes synuclein
T123 1258-1267 D051843 denotes synuclein
T125 1337-1347 SO:0000783 denotes engineered
T126 1348-1353 PR:Q5S006 denotes LRRK2
T127 1348-1353 PR:000003033 denotes LRRK2
T128 1348-1353 PR:Q5S007 denotes LRRK2
T129 1357-1361 PR:000005054 denotes mice
T131 1357-1361 O89094 denotes mice
T130 1357-1361 D051379 denotes mice
T132 1357-1361 10095 denotes mice
T133 1424-1428 PR:000005054 denotes mice
T135 1424-1428 O89094 denotes mice
T134 1424-1428 D051379 denotes mice
T136 1424-1428 10095 denotes mice
T137 1522-1537 GO:0016301 denotes kinase activity
T138 1547-1552 PR:Q5S006 denotes LRRK2
T139 1547-1552 PR:000003033 denotes LRRK2
T140 1547-1552 PR:Q5S007 denotes LRRK2
T141 1560-1568 SO:0000109 denotes mutation
T143 1661-1666 PR:Q5S006 denotes LRRK2
T144 1661-1666 PR:000003033 denotes LRRK2
T145 1661-1666 PR:Q5S007 denotes LRRK2
T146 1720-1725 PR:Q5S006 denotes LRRK2
T147 1720-1725 PR:000003033 denotes LRRK2
T148 1720-1725 PR:Q5S007 denotes LRRK2

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 145-405 DRI_Approach denotes Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified as an unambiguous cause of late-onset, autosomal-dominant familial Parkinson's disease (PD) and LRRK2 mutations are the strongest genetic risk factor for sporadic PD known to date.
T2 406-566 DRI_Background denotes A number of transgenic mice expressing wild-type or mutant LRRK2 have been described with varying degrees of LRRK2-related abnormalities and modest pathologies.
T3 567-733 DRI_Background denotes None of these studies directly addressed the role of the kinase domain in the changes observed and none of the mice present with robust features of the human disease.
T4 734-797 DRI_Approach denotes In an attempt to address these issues, we created a conditional
T5 811-865 DRI_Approach denotes (LRRK2 GS) mutant and a functionally negative control,
T6 886-887 DRI_Approach denotes (
T7 898-900 DRI_Approach denotes ).
T8 901-926 DRI_Approach denotes Expression of LRRK2 GS or
T9 939-1136 DRI_Approach denotes was conditionally controlled using the tet-off system in which the presence of tetracycline-transactivator protein (tTA) with a CAMKIIα promoter (CAMKIIα-tTA) induced expression of TetP-LRRK2 GS or
T10 1154-1177 DRI_Approach denotes in the mouse forebrain.
T11 1178-1307 DRI_Challenge denotes Overexpression of LRRK2 GS in mouse forebrain induced behavioral deficits and α-synuclein pathology in a kinase-dependent manner.
T12 1308-1417 DRI_Outcome denotes Similar to other genetically engineered LRRK2 GS mice, there was no significant loss of dopaminergic neurons.
T13 1418-1546 DRI_Challenge denotes These mice provide an important new tool to study neurobiological changes associated with the increased kinase activity from the
T14 1560-1719 DRI_Challenge denotes mutation, which may ultimately lead to a better understanding of not only the physiologic actions of LRRK2, but also potential pathologic actions that underlie
T15 1740-1743 DRI_Challenge denotes PD.